We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Adcomm Recommends Brintellix to Treat Cognitive Dysfunction
FDA Adcomm Recommends Brintellix to Treat Cognitive Dysfunction
The FDA’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 to support a new claim for Takeda’s Brintellix for the treatment of cognitive dysfunction in major depressive disorder.